Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis

Hepatology Research

Volumn 44, Issue 6, 2014, Pages 621-630

  Liu, Lei ^a   Zhao, Yan ^a   Qi, Xingshun ^a   Cai, Guohong ^a   He, Chuangye ^a   Guo, Wengang ^a   Yin, Zhanxin ^a   Chen, Hui ^a   Chen, Xi ^a   Fan, Daiming ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Portal hypertension; Portal vein tumor thrombosis; Therapy; Transjugular intrahepatic portosystemic shunt

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; BLEEDING; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; HUMAN; HYDROTHORAX; LEUKOCYTE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PORTAL VEIN TUMOR THROMBOSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL TIME; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TUMOR THROMBUS;

EID: 84901922558     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12162     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56 (Suppl 1): S75-87.
3. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-1283.
4. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233: 379-384.
5. Garcia-Pagan JC, Caca K, Bureau C etal. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-2379.
6. Luca A, Miraglia R, Caruso S etal. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60: 846-852.
7. Wallace MJ, Madoff DC, Ahrar K, Warneke CL. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting. Cancer 2004; 101: 337-345.
8. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400.
9. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
10. Han G, Qi X, He C etal. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011; 54: 78-88.
11. Qi X, Han G, Yin Z etal. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci 2012; 57: 1072-1082.
12. Qi X, Han G, Wang J, Wu K, Fan D. Degree of portal vein thrombosis. Hepatology 2010; 51: 1089-1090.
13. Qi X, Han G, He C etal. CT features of non-malignant portal vein thrombosis: a pictorial review. Clin Res Hepatol Gastroenterol 2012; 36: 561-568.
14. Moore KP, Wong F, Gines P etal. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-266.
15. Thalheimer U, Leandro G, Samonakis DN etal. TIPS for refractory ascites: a single-centre experience. J Gastroenterol 2009; 44: 1089-1095.
16. Qi X, Han G. Transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis: a critical review of literature. Hepatol Int 2012; 6: 576-590.
17. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008; 28: 3-25.
18. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
19. Hur J, Lee KH, Lee JH, Yu JS, Won JY, Lee DY. Stent-graft for TIPS in a hepatocellular carcinoma patient with main portal vein invasion. AJR Am J Roentgenol 2004; 182: 1301-1304.
20. Burger JA, Ochs A, Wirth K etal. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 1997; 8: 200-202.
21. Bezzi M, Broglia L, Lemos AA, Rossi P. Transjugular intrahepatic portosystemic shunt in portal vein thrombosis: role of the right gastric vein with anomalous insertion. Cardiovasc Intervent Radiol 1995; 18: 102-105.
22. Jiang ZB, Shan H, Shen XY etal. Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis. WJG 2004; 10: 1881-1884.
23. Radosevich PM, Ring EJ, LaBerge JM etal. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology 1993; 186: 523-527.
24. Bilbao JI, Elorz M, Vivas I, Martinez-Cuesta A, Bastarrika G, Benito A. Transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of venous symptomatic chronic portal thrombosis in non-cirrhotic patients. Cardiovasc Intervent Radiol 2004; 27: 474-480.
25. Liu CL, Fan ST, Lo CM etal. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19: 3725-3732.
26. Wallace MJ, Madoff DC. Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy. Semin Intervent Radiol 2005; 22: 309-315.
27. Nagral AS, Joshi AS, Bhatia SJ, Abraham P, Mistry FP, Vora IM. Congestive jejunopathy in portal hypertension. Gut 1993; 34: 694-697.
28. Connolly GC, Chen R, Hyrien O etal. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008; 122: 299-306.
29. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
30. Cabibbo G, Rolle E, De Giorgio M etal. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther 2011; 11: 1807-1816.